| 1 |
陈利，朱风尚，杨长青．非酒精性脂肪性肝炎相关肝细胞癌特征及诊治进展[J/OL]．中华消化病与影像杂志(电子版)，2020，10(6)：49-51.
|
| 2 |
He LH，Yao DH，Wang LY，et al.Gut Microbiome-Mediated Alteration of Immunity，Inflammation，and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease[J]．Front Microbiol，2021，12：761836.
|
| 3 |
Quesada-Vázquez S，Aragonès G，Del Bas JM，et al.Diet，Gut Microbiota and Non-Alcoholic Fatty Liver Disease：Three Parts of the Same Axis[J]．Cells，2020，9(1)：176.
|
| 4 |
Castillo V，Figueroa F，González-Pizarro K，et al.Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease，a Narrative Review[J]．Foods，2021，10(8)：1719.
|
| 5 |
Chen J，Vitetta L．Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications[J]．Int J Mol Sci，2020，21(15)：5214.
|
| 6 |
Aron-Wisnewsky J，Vigliotti C，Witjes J，et al.Gut microbiota and human NAFLD：disentangling microbial signatures from metabolic disorders[J]．Nat Rev Gastroenterol Hepatol，2020，17(5)：279-297.
|
| 7 |
Crommen S，Rheinwalt KP，Plamper A，et al.A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery[J]．J Nutr，2022，152(2)：408-418.
|
| 8 |
Sherf-Dagan S，Zelber-Sagi S，Zilberman-Schapira G，et al.Probiotics administration following sleeve gastrectomy surgery：a randomized double-blind trial[J]．Int J Obes(Lond)，2018，42(2)：147-155.
|
| 9 |
Vallianou N，Christodoulatos GS，Karampela I，et al.Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease：Current Evidence and Perspectives[J]．Biomolecules，2021，12(1)：56.
|
| 10 |
Anstee QM，Hallsworth K，Lynch N，et al.Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions[J]．JHEP Rep，2021，4(1)：100411.
|
| 11 |
Gibson GR，Hutkins R，Sanders ME，et al.Expert consensus document：The International Scientific Association for Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of prebiotics[J]．Nat Rev Gastroenterol Hepatol，2017，14(8)：491-502.
|
| 12 |
Kerry RG，Das G，Golla U，et al.Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders：A Review[J]．Curr Pharm Biotechnol，2022，23(1)：72-97.
|
| 13 |
Beserra BT，Fernandes R，do Rosario VA，et al.A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia，insulin concentrations and lipid parameters in adult patients with overweight or obesity[J]．Clin Nutr，2015，34(5)：845-858.
|
| 14 |
Stachowska E，Portincasa P，Jamio-Milc D，et al.The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]．Nutrients，2020，12(11)：3460.
|
| 15 |
Nagashimada M，Honda M．Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics，Prebiotics，and Biogenics[J]．Int J Mol Sci，2021，22(15)：8008.
|
| 16 |
Keulers L，Dehghani A，Knippels L，et al.Probiotics，prebiotics，and synbiotics to prevent or combat air pollution consequences：The gut-lung axis[J]．Environ Pollut，2022，302：119066.
|
| 17 |
Eslamparast T，Poustchi H，Zamani F，et al.Synbiotic supplementation in nonalcoholic fatty liver disease：a randomized，double-blind，placebo-controlled pilot study[J]．Am J Clin Nutr，2014，99(3)：535-542.
|
| 18 |
Malaguarnera M，Vacante M，Antic T，et al.Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]．Dig Dis Sci，2012，57(2)：545-553.
|
| 19 |
Khan MY，Mihali AB，Rawala MS，et al.The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease-a systematic review and meta-analysis[J]．Eur J Gastroenterol Hepatol，2019，31(6)：703-715.
|
| 20 |
Asgharian A，Askari G，Esmailzade A，et al.The Effect of Symbiotic Supplementation on Liver Enzymes，C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease：A Clinical Trial[J]．Int J Prev Med，2016，7：59.
|
| 21 |
Scorletti E，Afolabi PR，Miles EA，et al.Synbiotics Alter Fecal Microbiomes，But Not Liver Fat or Fibrosis，in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease[J]．Gastroenterology，2020，158(6)：1597-1610.
|
| 22 |
Salminen S，Collado MC，Endo A，et al.The International Scientific Association of Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of postbiotics[J]．Nat Rev Gastroenterol Hepatol，2021，18(9)：649-667.
|
| 23 |
Liu Y，Wang J，Wu C．Modulation of Gut Microbiota and Immune System by Probiotics，Pre-biotics，and Post-biotics[J]．Front Nutr，2022，8：634897.
|
| 24 |
Zhou D，Pan Q，Xin FZ，et al.Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier[J]．World J Gastroenterol，2017，23(1)：60-75.
|
| 25 |
Jin H，Xu X，Pang B，et al.Probiotic and prebiotic interventions for non-alcoholic fatty liver disease：a systematic review and network meta-analysis[J]．Benef Microbes，2021，12(6)：517-529.
|
| 26 |
Sakurai Y，Watanabe T，Miura Y，et al.Clinical and Bacteriologic Characteristics of Six Cases of Bifidobacterium breve Bacteremia Due to Probiotic Administration in the Neonatal Intensive Care Unit[J]．Pediatr Infect Dis J，2022，41(1)：62-65.
|
| 27 |
Colosimo S，Ravaioli F，Petroni ML，et al.Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes：A real-world data analysis[J]．Liver Int，2021，41(4)：731-742.
|